Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers

Hui Cai, Elena G. Chiorean, Michael V. Chiorean, Douglas K. Rex, Bruce W. Robb, Noah Hahn, Ziyue Liu, Patrick J. Loehrer, Marietta L. Harrison, Yan Xu

Research output: Contribution to journalArticle

Abstract

Only in recent years have phospholipase A2 enzymes (PLA2s) emerged as cancer targets. In this work, we report the first detection of elevated PLA2 activities in plasma from patients with colorectal, lung, pancreatic, and bladder cancers as compared to healthy controls. Independent sets of clinical plasma samples were obtained from two different sites. The first set was from patients with colorectal cancer (CRC; n = 38) and healthy controls (n = 77). The second set was from patients with lung (n = 95), bladder (n = 31), or pancreatic cancers (n = 38), and healthy controls (n = 79). PLA2 activities were analyzed by a validated quantitative fluorescent assay method and subtype PLA2 activities were defined in the presence of selective inhibitors. The natural PLA2 activity, as well as each subtype of PLA2 activity was elevated in each cancer group as compared to healthy controls. PLA2 activities were increased in late stage vs. early stage cases in CRC. PLA2 activities were not influenced by sex, smoking, alcohol consumption, or body-mass index (BMI). Samples from the two independent sites confirmed the results. Plasma PLA2 activities had approximately 70% specificity and sensitivity to detect cancer. The marker and targeting values of PLA2 activity have been suggested.

Original languageEnglish (US)
Article numbere57081
JournalPLoS One
Volume8
Issue number2
DOIs
StatePublished - Feb 22 2013
Externally publishedYes

Fingerprint

phospholipase A2
Phospholipases A2
pancreatic neoplasms
colorectal neoplasms
Pancreatic Neoplasms
Plasmas
neoplasms
Colorectal Neoplasms
Neoplasms
lung neoplasms
bladder
Urinary Bladder Neoplasms
sampling
Alcohol Drinking
body mass index
Lung Neoplasms
Urinary Bladder
Body Mass Index
Smoking
lungs

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cai, H., Chiorean, E. G., Chiorean, M. V., Rex, D. K., Robb, B. W., Hahn, N., ... Xu, Y. (2013). Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers. PLoS One, 8(2), [e57081]. https://doi.org/10.1371/journal.pone.0057081

Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers. / Cai, Hui; Chiorean, Elena G.; Chiorean, Michael V.; Rex, Douglas K.; Robb, Bruce W.; Hahn, Noah; Liu, Ziyue; Loehrer, Patrick J.; Harrison, Marietta L.; Xu, Yan.

In: PLoS One, Vol. 8, No. 2, e57081, 22.02.2013.

Research output: Contribution to journalArticle

Cai, H, Chiorean, EG, Chiorean, MV, Rex, DK, Robb, BW, Hahn, N, Liu, Z, Loehrer, PJ, Harrison, ML & Xu, Y 2013, 'Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers', PLoS One, vol. 8, no. 2, e57081. https://doi.org/10.1371/journal.pone.0057081
Cai, Hui ; Chiorean, Elena G. ; Chiorean, Michael V. ; Rex, Douglas K. ; Robb, Bruce W. ; Hahn, Noah ; Liu, Ziyue ; Loehrer, Patrick J. ; Harrison, Marietta L. ; Xu, Yan. / Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers. In: PLoS One. 2013 ; Vol. 8, No. 2.
@article{0f55df132e7240a58d3af7a95ea1e184,
title = "Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers",
abstract = "Only in recent years have phospholipase A2 enzymes (PLA2s) emerged as cancer targets. In this work, we report the first detection of elevated PLA2 activities in plasma from patients with colorectal, lung, pancreatic, and bladder cancers as compared to healthy controls. Independent sets of clinical plasma samples were obtained from two different sites. The first set was from patients with colorectal cancer (CRC; n = 38) and healthy controls (n = 77). The second set was from patients with lung (n = 95), bladder (n = 31), or pancreatic cancers (n = 38), and healthy controls (n = 79). PLA2 activities were analyzed by a validated quantitative fluorescent assay method and subtype PLA2 activities were defined in the presence of selective inhibitors. The natural PLA2 activity, as well as each subtype of PLA2 activity was elevated in each cancer group as compared to healthy controls. PLA2 activities were increased in late stage vs. early stage cases in CRC. PLA2 activities were not influenced by sex, smoking, alcohol consumption, or body-mass index (BMI). Samples from the two independent sites confirmed the results. Plasma PLA2 activities had approximately 70{\%} specificity and sensitivity to detect cancer. The marker and targeting values of PLA2 activity have been suggested.",
author = "Hui Cai and Chiorean, {Elena G.} and Chiorean, {Michael V.} and Rex, {Douglas K.} and Robb, {Bruce W.} and Noah Hahn and Ziyue Liu and Loehrer, {Patrick J.} and Harrison, {Marietta L.} and Yan Xu",
year = "2013",
month = "2",
day = "22",
doi = "10.1371/journal.pone.0057081",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers

AU - Cai, Hui

AU - Chiorean, Elena G.

AU - Chiorean, Michael V.

AU - Rex, Douglas K.

AU - Robb, Bruce W.

AU - Hahn, Noah

AU - Liu, Ziyue

AU - Loehrer, Patrick J.

AU - Harrison, Marietta L.

AU - Xu, Yan

PY - 2013/2/22

Y1 - 2013/2/22

N2 - Only in recent years have phospholipase A2 enzymes (PLA2s) emerged as cancer targets. In this work, we report the first detection of elevated PLA2 activities in plasma from patients with colorectal, lung, pancreatic, and bladder cancers as compared to healthy controls. Independent sets of clinical plasma samples were obtained from two different sites. The first set was from patients with colorectal cancer (CRC; n = 38) and healthy controls (n = 77). The second set was from patients with lung (n = 95), bladder (n = 31), or pancreatic cancers (n = 38), and healthy controls (n = 79). PLA2 activities were analyzed by a validated quantitative fluorescent assay method and subtype PLA2 activities were defined in the presence of selective inhibitors. The natural PLA2 activity, as well as each subtype of PLA2 activity was elevated in each cancer group as compared to healthy controls. PLA2 activities were increased in late stage vs. early stage cases in CRC. PLA2 activities were not influenced by sex, smoking, alcohol consumption, or body-mass index (BMI). Samples from the two independent sites confirmed the results. Plasma PLA2 activities had approximately 70% specificity and sensitivity to detect cancer. The marker and targeting values of PLA2 activity have been suggested.

AB - Only in recent years have phospholipase A2 enzymes (PLA2s) emerged as cancer targets. In this work, we report the first detection of elevated PLA2 activities in plasma from patients with colorectal, lung, pancreatic, and bladder cancers as compared to healthy controls. Independent sets of clinical plasma samples were obtained from two different sites. The first set was from patients with colorectal cancer (CRC; n = 38) and healthy controls (n = 77). The second set was from patients with lung (n = 95), bladder (n = 31), or pancreatic cancers (n = 38), and healthy controls (n = 79). PLA2 activities were analyzed by a validated quantitative fluorescent assay method and subtype PLA2 activities were defined in the presence of selective inhibitors. The natural PLA2 activity, as well as each subtype of PLA2 activity was elevated in each cancer group as compared to healthy controls. PLA2 activities were increased in late stage vs. early stage cases in CRC. PLA2 activities were not influenced by sex, smoking, alcohol consumption, or body-mass index (BMI). Samples from the two independent sites confirmed the results. Plasma PLA2 activities had approximately 70% specificity and sensitivity to detect cancer. The marker and targeting values of PLA2 activity have been suggested.

UR - http://www.scopus.com/inward/record.url?scp=84874313790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874313790&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0057081

DO - 10.1371/journal.pone.0057081

M3 - Article

C2 - 23451150

AN - SCOPUS:84874313790

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e57081

ER -